eM Client: eM Client Acquires Postbox Inc., Expanding Its Reach to a Broader User Base

The acquisition solidifies eM Client’s position as a leading email client provider, bringing its innovative solutions to a growing audience.
Prague, October 23, 2024 – eM Client, a leading provider of email client software, announced its acquisition of Postbox Inc., a well-established email application company based in the United States. This acquisition enables eM Client to extend its innovative solutions to an even larger global audience, reinforcing its position as one of the most comprehensive email platforms available.
Summary:
- Who: eM Client has acquired Postbox Inc.
- What: The acquisition expands eM Client’s reach to a broader user base.
- When: October 22, 2024.
- Where: eM Client is based in Prague and serves a global customer base.
- Why: The acquisition strengthens eM Client’s leadership in the email client industry and brings its powerful tools to more users.
eM Client has established itself as a top choice for email users, integrating email, calendars, contacts, tasks, and notes in one seamless platform. Its latest version offers advanced features, including generative AI message composition and editing features, integrated chat, group communication tools like MS Teams and Slack, and robust calendar functionality. As part of its commitment to innovation, eM Client continues to evolve and enhance its platform to meet the needs of modern professionals.
"We are excited to welcome Postbox users to eM Client," said Michal Burger, CEO of eM Client. "I believe they will be delighted by the transition, as both applications emphasize innovation, productivity, and ease of use. We look forward to providing them with our full suite of tools designed to optimize email and communication management."
eM Client offers one-time purchase and subscription-based licensing models, making it an ideal solution for individuals and businesses. With over 2.5 million users and more than 100,000 companies worldwide, eM Client is known for its reliability, innovative features, and professional support.
About eM Client
Founded in 2006, eM Client (www.emclient.com) is a global leader in email client software. It offers a unified platform for managing email, calendars, contacts, tasks, and notes. Trusted by millions of users for its ease of use and powerful features, including AI integration and support for multiple communication tools, eM Client is committed to providing an all-in-one solution for modern communication needs.
About Postbox Inc.
Founded in 2008, Postbox Inc. (www.postbox-inc.com) is known for attracting productivity-focused professionals and power users who demand efficiency in email management. Recognized for its expansive user base, Postbox has served individuals and businesses that rely on streamlined workflows and high productivity in their daily communications.
Contact Information:
For press inquiries, please contact:
eM Client
info@emclient.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom